查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006253

CRISPR技術市場：按交付方式、應用和最終用戶分類－2026-2032年全球市場預測

CRISPR Technology Market by Offering, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，CRISPR 技術市場價值將達到 40.2 億美元，到 2026 年將成長至 45.7 億美元，到 2032 年將達到 103.2 億美元，複合年成長率為 14.41%。

主要市場統計數據
基準年 2025 40.2億美元
預計年份：2026年 45.7億美元
預測年份 2032 103.2億美元
複合年成長率 (%) 14.41%

本文簡要概述了 CRISPR 的科學基礎和轉化研究軌跡，闡明了其技術支柱、法規環境和商業性意義。

CRISPR 工具包融合了分子生物學、電腦設計和轉化研究，能夠對多種生物的基因組進行精確編輯。酵素工程、引導 RNA 最佳化、遞送技術和篩檢平台等方面的進步，共同推動了 CRISPR 從一項實驗室技術發展成為應用生命科學的核心能力。隨著基礎科學發現的不斷成熟，研究機構和企業正日益致力於將基因編輯應用於治療方法、農業改良、診斷和工業生物製程等領域。

核酸酶、引導設計和遞送系統的技術進步如何重新定義 CRISPR 價值鍊和應用趨勢？

CRISPR技術的未來正經歷著一場變革性的轉變，這主要得益於酵素的多樣化、電腦輔助引導RNA設計的整合以及先進遞送系統的創新。新開發的核酸酶和鹼基編輯器拓展了可編輯的基因類型，而引導RNA化學性質的改進和演算法設計的進步則提高了特異性並減少了脫靶效應。同時，脂質體製劑、標靶化病毒載體和體外細胞修飾等遞送策略正在拓展CRISPR技術在治療和農業領域的應用範圍，進而重塑其價值鏈。

我們將評估美國近期關稅措施對 CRISPR 供應鏈、採購和製造決策的一系列營運和策略影響。

美國近期實施的關稅措施和貿易政策調整，為全球CRISPR供應鏈引入了新的變數，影響了試劑、儀器和外包服務的籌資策略。進口關稅的提高以及相關的合規要求可能會增加海外採購組件的總體成本，給研究機構和製造商帶來行政負擔。為此，許多相關人員正在重新審視與供應商的關係，將採購來源多元化，轉向其他地區，並增加庫存以應對價格波動。

將產品和服務組合、交付方式、應用領域和最終用戶概況與營運風險和策略重點連結起來的多維細分分析。

從實際觀點進行市場細分，可以清楚了解每種產品/服務、交付方式、應用領域和最終用戶的價值和風險集中在哪裡。基於產品/服務，市場可分為「產品」與「服務」兩大類。產品類包括酵素、引導RNA、試劑盒和試劑等核心組件，而服務類則包括細胞株建構、gRNA設計和載體建構等實驗室功能，以及將平台潛力轉化為實驗結果的篩檢服務。這種產品/服務的區分有助於企業優先考慮對內部能力和外部專業知識的投資。

美洲、歐洲、中東和非洲以及亞太地區的法規環境、人才庫和製造地對 CRISPR 採用和合作策略的影響。

區域趨勢影響人才獲取、監管路徑、供應鏈韌性和夥伴關係系統。美洲擁有大規模研究型大學、創業投資集群和完善的臨床試驗基礎設施，在治療藥物的研發和商業化方面正蓬勃發展。該地區的生態系統優先考慮將有前景的治療方法快速轉化為早期臨床研究，並傾向於支持學術發明者和商業夥伴之間的深度合作。

深入了解試劑開發商、服務提供者和策略合作夥伴如何建立能力、合作夥伴關係和卓越運營，以推動 CRISPR 專案。

主要企業的發展趨勢凸顯了各組織如何將技術能力轉化為市場吸引力。成熟的核心試劑和設備開發人員持續投資於酵素工程、試劑品管和可擴展試劑盒設計，以滿足科研實驗室和受監管開發項目的需求。同時，專業服務供應商正透過整合gRNA設計、載體建構、細胞株工程和高通量篩檢等服務來脫穎而出，幫助客戶縮短藥物研發週期。

為產業領導者提供可操作的策略重點，以建立韌性能力、實現供應鏈多元化並加速負責任地實用化CRISPR 創新技術。

尋求永續競爭優勢的領導企業應採取平衡策略，將能力建構與風險規避結合。首先，企業應優先發展內部模組化能力，以應對酵素品管和gRNA檢驗等關鍵路徑活動，同時將專業化或規模依賴職能外包給值得信賴的服務供應商。這種混合模式既能保持靈活性，又能有效控制知識產權和技術標準。

為了支持實際見解，我們採用嚴格的混合方法研究途徑，結合專家訪談、文獻整合和以可重複性為重點的資料檢驗。

本調查方法融合了初步研究、專家訪談和系統性文獻整合，以產生嚴謹客觀的分析。初步研究包括與學術界、生物技術公司、受託研究機構和製藥研發公司的技術領導者進行結構化訪談，以了解實際營運中的限制和不斷變化的需求。專家訪談則提供了關於酵素創新、遞送挑戰和監管趨勢的深入定性分析，從而能夠將實踐者的觀點與文獻證據進行比較。

整合 CRISPR 在科學、操作和監管方面的成熟度，並確定當前面臨的挑戰和短期實用化。

CRISPR技術已從一項突破性的科學發現發展成為一個基礎平台，其具體實用化途徑涵蓋治療、農業、診斷和工業生物技術等領域。儘管酶工程、引導序列設計、遞送方法和整合服務的進步降低了技術門檻，但在遞送特異性、監管合規性和供應鏈韌性方面仍然存在挑戰。隨著應用範圍的擴大，技術、監管和商業性因素的相互作用將決定哪些應用能夠率先達到臨床和市場成熟階段。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 CRISPR技術市場：依產品/服務分類

  • 產品
    • 酵素
    • 引導RNA
    • 試劑盒和試劑
  • 服務
    • 細胞株工程
    • gRNA設計與載體構建
    • 篩檢服務

第9章 CRISPR技術市場：依交付方式分類

  • Ex Vivo
    • 細胞株改造
    • 原代細胞修飾
  • In vivo
    • 直接編輯
    • 奈米顆粒遞送
    • 重定向載體

第10章 CRISPR技術市場：按應用分類

  • 農業用途
    • 畜牧養殖
    • 抗蟲害
  • 生物醫學應用
    • 藥物發現與開發
    • 基因治療
  • 診斷
  • 工業生物技術
    • 生質燃料生產
    • 微生物菌株的改造

第11章：CRISPR技術市場：依最終用戶分類

  • 學術和研究機構
  • 生技公司
  • 合約研究機構
  • 製藥公司

第12章：CRISPR技術市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：CRISPR技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：CRISPR技術市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國CRISPR技術市場

第16章 中國CRISPR技術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AgBiome Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Beam Therapeutics Inc.
  • Benson Hill Biosystems, Inc.
  • Caribou Biosciences, Inc.
  • Cibus Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GeneCopoeia, Inc.
  • Genscript Biotech Corporation
  • Hera BioLabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • Pairwise Foods Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Syngenta AG
  • Thermo Fisher Scientific, Inc.
  • ToolGen Inc,
  • Yield10 Bioscience, Inc.
Product Code: MRR-B1685377A648

The CRISPR Technology Market was valued at USD 4.02 billion in 2025 and is projected to grow to USD 4.57 billion in 2026, with a CAGR of 14.41%, reaching USD 10.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.02 billion
Estimated Year [2026] USD 4.57 billion
Forecast Year [2032] USD 10.32 billion
CAGR (%) 14.41%

A concise overview of CRISPR's scientific foundations and translational trajectory that frames technological pillars, regulatory context, and commercial relevance

The CRISPR toolkit sits at the intersection of molecular biology, computational design, and translational research, enabling precise edits of genomes across diverse organisms. Advancements in enzyme engineering, guide RNA optimization, delivery modalities, and screening platforms have collectively moved CRISPR from a laboratory technique into a core capability for applied life sciences. As basic science discoveries have matured, institutions and companies are increasingly focused on translating gene editing into therapeutics, agricultural improvements, diagnostics, and industrial bioprocessing.

This introduction frames the report's scope by highlighting the technical pillars-nuclease chemistry, guide design, reagent quality, and delivery strategies-that underpin performance and adoption. It also situates CRISPR within an evolving ecosystem of regulatory scrutiny, ethical debate, and supply chain dynamics. Readers should expect an evidence-based synthesis that balances molecular detail with commercial realities, supporting informed choices across research, product development, and strategic investment.

How converging technological advances in nucleases, guide design, and delivery systems are redefining the CRISPR value chain and adoption dynamics

The landscape of CRISPR technology is undergoing transformative shifts driven by converging innovations in enzyme diversification, computational guide design, and sophisticated delivery systems. New engineered nucleases and base editors have expanded the repertoire of achievable edits, while advances in guide RNA chemistry and algorithmic design are improving specificity and reducing off-target effects. In parallel, delivery strategies such as lipid nanoparticle formulations, retargeted viral vectors, and ex vivo cell modification approaches are enabling broader therapeutic and agricultural applications, thereby reshaping the value chain.

Concurrently, institutional adoption patterns are changing: academic groups, biotech companies, contract research organizations, and pharmaceutical developers are reallocating resources to integrate CRISPR into pipelines for drug discovery, cell therapies, diagnostic assays, and strain engineering. Strategic collaborations and licensing arrangements are increasingly common as organizations seek to combine platform strengths with clinical or commercialization expertise. Regulatory frameworks and public discourse around ethical use are also maturing, prompting companies to invest in compliance, transparency, and stakeholder engagement to accelerate responsible deployment.

Evaluating the cascading operational and strategic effects of recent United States tariff actions on CRISPR supply chains, procurement, and manufacturing decisions

Recent tariff measures and trade policy adjustments implemented by the United States have introduced new variables into global CRISPR supply chains, affecting procurement strategies for reagents, instruments, and outsourced services. Elevated import duties and related compliance requirements can increase landed costs for components sourced internationally and create administrative overhead for research organizations and manufacturers. In response, many stakeholders are reassessing supplier relationships, diversifying procurement to alternate geographies, and increasing inventories to buffer against volatility.

The tariff environment also influences strategic location decisions for manufacturing and service activities. Companies that rely on specialized enzymes, guide RNA synthesis, or kits and reagents may accelerate efforts to localize production or to develop alternative sourcing models, including partnerships with contract manufacturers within tariff-favored jurisdictions. Importantly, the cumulative impact extends beyond pricing: it reshapes contractual terms, lengthens lead times for critical inputs, and can alter timelines for development programs. Consequently, organizations with international operations are prioritizing supply chain transparency, scenario planning, and contract clauses that mitigate tariff exposure while preserving research continuity.

A multidimensional segmentation analysis linking product and service portfolios, delivery approaches, application areas, and end-user profiles to operational risks and strategic priorities

A practical segmentation perspective clarifies where value and risk concentrate across offerings, delivery modalities, applications, and end users. Based on offering, the landscape divides into Product and Services: Product pathways encompass core components such as enzymes, guide RNA, and kits & reagents, while Services include laboratory capabilities like cell line engineering, gRNA design & vector construction, and screening services that convert platform potential into experimental outcomes. These offering distinctions help organizations prioritize investments in in-house capabilities versus outsourced expertise.

Based on delivery method, distinctions between Ex Vivo and In Vivo approaches shape technical and regulatory requirements. Ex Vivo strategies further segment into cell line modification and primary cell modification, each with unique manufacturing, cell handling, and quality control needs. In Vivo delivery subdivides into direct editing, nanoparticle delivery, and retargeting vectors, where biodistribution, immunogenicity, and long-term expression profiles inform development choices. Based on application, CRISPR use cases span agricultural applications, biomedical applications, diagnostics, and industrial biotechnology; agricultural efforts include livestock breeding and pest resistance, biomedical efforts emphasize drug discovery & development and gene therapy, and industrial biotechnology focuses on biofuel production and microbial strain engineering. Based on end-user, demand originates from academic & research institutes, biotech companies, contract research organizations, and pharmaceutical companies, each bringing different procurement cycles, validation expectations, and collaboration models. Collectively, these segmentation lenses reveal where technical complexity, regulatory friction, and commercial opportunity overlap, guiding prioritization of capability building and partnership formation.

How regional regulatory environments, talent pools, and manufacturing hubs across the Americas, Europe Middle East & Africa, and Asia-Pacific shape CRISPR adoption and collaboration strategies

Regional dynamics influence talent access, regulatory pathways, supply chain resilience, and partnership ecosystems. In the Americas, home to large research universities, venture capital concentration, and established clinical trial infrastructures, there is strong momentum for therapeutic development and commercialization. The region's ecosystem tends to favor rapid translation of promising modalities into early-stage clinical work and to support deep collaborations between academic inventors and commercial partners.

Europe, Middle East & Africa present a heterogeneous environment where divergent regulatory regimes and public attitudes shape program design. Several European jurisdictions combine robust scientific capabilities with conservative regulatory evaluation, prompting companies to adopt deliberate engagement strategies and to invest in transparent safety data. Meanwhile, Middle Eastern and African markets show growing interest in agricultural and industrial biotechnology applications, with an emphasis on capacity building. Asia-Pacific exhibits a mix of rapid technical adoption, localized manufacturing strengths, and significant government-backed initiatives to support biotechnology. The region's expansive manufacturing base for reagents and instruments, coupled with advancing clinical capabilities, positions it as a critical node for both supply and collaborative development.

Insights into how reagent developers, service specialists, and strategic partners are structuring capabilities, alliances, and operational excellence to advance CRISPR programs

Key corporate behaviors illuminate how organizations translate technological capability into market traction. Established developers of core reagents and instruments continue to invest in enzyme engineering, reagent quality control, and scalable kit design to meet the demands of both research labs and regulated development programs. Parallel to this, specialized service providers are differentiating through integrated offerings that combine gRNA design, vector construction, and cell line engineering with high-throughput screening, enabling customers to compress discovery timelines.

Strategic alliances and licensing arrangements remain central to scaling complex therapeutic programs, with companies forming cross-sector partnerships to access clinical expertise, manufacturing capacity, or regulatory experience. Contract research organizations and contract manufacturing organizations demonstrate increasing vertical integration, offering end-to-end support from assay development through GMP production. Firms that prioritize robust quality management systems, transparent data packages, and regulatory engagement gain trust from pharmaceutical sponsors and academic collaborators, reinforcing their role in translational pipelines. Taken together, these behaviors underscore that commercial success hinges on technical excellence plus the operational capabilities to support regulated development pathways.

Actionable strategic priorities for industry leaders to build resilient capabilities, diversify supply chains, and accelerate responsible translation of CRISPR innovations

Leaders seeking sustainable advantage should adopt a balanced playbook that combines capability investment with risk mitigation. First, organizations should prioritize modular in-house capabilities for critical-path activities such as enzyme quality control and gRNA validation while outsourcing specialized or scale-dependent functions to trusted service providers. This hybrid approach preserves control over intellectual property and technical standards while enabling agility.

Second, proactively harden supply chains by diversifying suppliers across jurisdictions and by qualifying secondary sources for high-risk inputs. Third, invest in regulatory intelligence and early engagement with authorities to align study designs, safety assessments, and manufacturing controls with evolving expectations. Fourth, cultivate partnerships that pair scientific novelty with clinical or commercial experience, ensuring that platform innovations translate into viable products. Finally, embed data governance, reproducibility practices, and transparent reporting into R&D workflows to build credibility with regulators, funders, and the public. Together, these actions create a resilient foundation for scaling CRISPR-enabled initiatives responsibly and efficiently.

A rigorous mixed-methods research approach combining expert consultations, literature synthesis, and reproducibility-focused data validation to underpin actionable insights

The research methodology integrates primary engagement, expert interviews, and systematic literature synthesis to generate a rigorous, objective analysis. Primary engagement included structured consultations with technical leaders across academia, biotechnology firms, contract research organizations, and pharmaceutical developers to capture real-world operational constraints and evolving requirements. Expert interviews provided qualitative depth on enzyme innovations, delivery challenges, and regulatory trajectories, enabling the study to triangulate practitioner perspectives with documented evidence.

Secondary research encompassed peer-reviewed scientific literature, regulatory guidance documents, patent landscapes, and publicly disclosed corporate materials to map technological progress and institutional behavior. Data synthesis emphasized reproducibility, cross-validation of claims, and contextual interpretation of technical performance metrics. Throughout the process, methodological safeguards were applied to minimize bias, including diverse expert sampling and transparent citation of sources used to inform technical assessments. The resulting methodology supports conclusions that are actionable for scientific, operational, and strategic audiences.

A synthesis of CRISPR's maturation across scientific, operational, and regulatory dimensions that identifies enduring challenges and near-term enablers of translation

CRISPR technology has progressed from a transformative scientific discovery to a foundational platform with tangible translational pathways across therapeutics, agriculture, diagnostics, and industrial biotechnology. Progress in enzyme engineering, guide design, delivery modalities, and integrated services has reduced technical barriers, yet persistent challenges remain in delivery specificity, regulatory alignment, and supply chain resilience. As adoption broadens, the interplay of technical, regulatory, and commercial considerations will determine which applications reach clinical and market maturity first.

Looking forward, stakeholders that invest in robust quality systems, diversify procurement strategies, and engage early with regulatory authorities will be best positioned to convert platform capability into sustainable products. Moreover, strategic partnerships that combine deep technical expertise with clinical development capacity will accelerate translation while distributing risk. In sum, CRISPR stands as a high-impact platform whose realized value will depend on coordinated advances in science, operations, and governance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR Technology Market, by Offering

  • 8.1. Product
    • 8.1.1. Enzymes
    • 8.1.2. Guide RNA
    • 8.1.3. Kits & Reagents
  • 8.2. Services
    • 8.2.1. Cell Line Engineering
    • 8.2.2. gRNA Design & Vector Construction
    • 8.2.3. Screening Services

9. CRISPR Technology Market, by Delivery Method

  • 9.1. Ex Vivo
    • 9.1.1. Cell Line Modification
    • 9.1.2. Primary Cell Modification
  • 9.2. In Vivo
    • 9.2.1. Direct Editing
    • 9.2.2. Nanoparticle Delivery
    • 9.2.3. Retargeting Vectors

10. CRISPR Technology Market, by Application

  • 10.1. Agricultural Applications
    • 10.1.1. Livestock Breeding
    • 10.1.2. Pest Resistance
  • 10.2. Biomedical Applications
    • 10.2.1. Drug Discovery & Development
    • 10.2.2. Gene Therapy
  • 10.3. Diagnostics
  • 10.4. Industrial Biotechnology
    • 10.4.1. Biofuel Production
    • 10.4.2. Microbial Strain Engineering

11. CRISPR Technology Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotech Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. CRISPR Technology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CRISPR Technology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CRISPR Technology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States CRISPR Technology Market

16. China CRISPR Technology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AgBiome Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. BASF SE
  • 17.8. Bayer AG
  • 17.9. Beam Therapeutics Inc.
  • 17.10. Benson Hill Biosystems, Inc.
  • 17.11. Caribou Biosciences, Inc.
  • 17.12. Cibus Inc.
  • 17.13. CRISPR Therapeutics AG
  • 17.14. Danaher Corporation
  • 17.15. Editas Medicine, Inc.
  • 17.16. GeneCopoeia, Inc.
  • 17.17. Genscript Biotech Corporation
  • 17.18. Hera BioLabs
  • 17.19. Intellia Therapeutics Inc.
  • 17.20. Lonza Group Ltd.
  • 17.21. Mammoth Biosciences, Inc.
  • 17.22. Merck KGaA
  • 17.23. Pairwise Foods Inc.
  • 17.24. Qiagen NV
  • 17.25. Revvity, Inc.
  • 17.26. Syngenta AG
  • 17.27. Thermo Fisher Scientific, Inc.
  • 17.28. ToolGen Inc,
  • 17.29. Yield10 Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRISPR TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 251. G7 CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. NATO CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. NATO CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 263. NATO CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 265. NATO CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. NATO CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)